Targeting the UPS as Therapy in Multiple Myeloma

DSpace/Manakin Repository

Targeting the UPS as Therapy in Multiple Myeloma

Show simple item record

dc.contributor.author Bianchi, Giada
dc.contributor.author Chauhan, Dharminder
dc.contributor.author Anderson, Kenneth Carl
dc.date.accessioned 2012-02-24T00:10:42Z
dc.date.issued 2008
dc.identifier.citation Chauhan, Dharminder, Giada Bianchi, and Kenneth C. Anderson. 2008. Targeting the UPS as therapy in multiple myeloma. BMC Biochemistry 9(Suppl 1): S1. en_US
dc.identifier.issn 1471-2091 en_US
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:8231689
dc.description.abstract The coordinated regulation of cellular protein synthesis and degradation is essential for normal cellular functioning. The ubiquitin proteasome system mediates the intracellular protein degradation that is required for normal cellular homeostasis. The 26S proteasome is a multi-enzyme protease that degrades redundant proteins; conversely, inhibition of proteasomal degradation results in intracellular aggregation of unwanted proteins and cell death. This observation led to the development of proteasome inhibitors as therapeutics for use in cancer. The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the first proteasome inhibitor, bortezomib, for the treatment of relapsed/refractory multiple myeloma. Although bortezomib represents a major advance in the treatment of this disease, it can be associated with toxicity and the development of drug resistance. Importantly, extensive preclinical studies suggest that combination therapies can both circumvent drug resistance and reduce toxicity. In addition, promising novel proteasome inhibitors, which are distinct from bortezomib, and exhibit equipotent anti-multiple myeloma activities, are undergoing clinical evaluation in order to improve patient outcome in multiple myeloma. Republished from Current BioData's Targeted Proteins database (TPdb; http://www.targetedproteinsdb.com). en_US
dc.language.iso en_US en_US
dc.publisher BioMed Central en_US
dc.relation.isversionof doi:10.1186/1471-2091-9-S1-S1 en_US
dc.relation.hasversion http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2582802/pdf/ en_US
dash.license LAA
dc.title Targeting the UPS as Therapy in Multiple Myeloma en_US
dc.type Journal Article en_US
dc.description.version Version of Record en_US
dc.relation.journal BMC Biochemistry en_US
dash.depositing.author Chauhan, Dharminder
dc.date.available 2012-02-24T00:10:42Z
dash.affiliation.other HMS^Medicine-Brigham and Women's Hospital en_US
dash.affiliation.other HMS^Medicine-Brigham and Women's Hospital en_US

Files in this item

Files Size Format View
2582802.pdf 358.9Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters